EP
AVIR icon

Essential Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Essential Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37K Buy
294
+245
+500% +$1.22K ﹤0.01% 2111
2026
Q1 		$264 Buy
+49
New +$225 ﹤0.01% 2569

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Essential Partners's AVIR Position: Q2 2026 in Review

Essential Partners increased its Atea Pharmaceuticals (AVIR) stake by 500% in Q2 2026, buying an estimated $1.22K and bringing the position to 294 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

Essential Partners first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Essential Partners held 294 shares of Atea Pharmaceuticals worth $1.37K as of Q2 2026.
  • Essential Partners bought 245 Atea Pharmaceuticals shares in Q2 2026, an estimated $1.22K.
  • Atea Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2111 holding.
  • Essential Partners first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.